Hypouricemic action of diflunisal in gouty patients: in vitro and in vivo studies.
Sixteen hyperuricemic gouty patients were treated with diflunisal, a novel salicylate, 500 mg BID. Serum and urine uric acid along with uric acid clearances were studied before and after a 7-day treatment. A clear hypouricemic action was observed, but 2 different mechanisms of action were seen when overexcretor patients and normoexcretor patients were analyzed separately. In overexcretors an allopurinol-like action was evident, whereas in normoexcretors a uricosuric action occurred. In vitro experiments showed a competitive inhibition of xanthine-oxidase exerted by diflunisal at low concentrations.
D000328:Adult; D000368:Aged; D003404:Creatinine / Q000652:urine; D004061:Diflunisal / Q000627:therapeutic use*; D004791:Enzyme Inhibitors; D006073:Gout / Q000188:drug therapy*; D006801:Humans; D066298:In Vitro Techniques; D008875:Middle Aged; D012459:Salicylates / Q000627:therapeutic use*; D014527:Uric Acid / Q000097:blood* / Q000652:urine; D014969:Xanthine Oxidase / Q000378:metabolism; D014970:Xanthines / Q000378:metabolism
D004791:Enzyme Inhibitors; D012459:Salicylates; D014970:Xanthines; D014527:Uric Acid; D004061:Diflunisal; D003404:Creatinine; D014969:Xanthine Oxidase